Диссертация (1140113), страница 17
Текст из файла (страница 17)
Pain. 1985. - p. 345-356.183.Kosinski M., Bayliss M.S., Bjorner J.B., Ware J. Jr., Garber W.H., Batenhorst A.,Cady R., Dahlöf C.G., Dowson A., Tepper S. A six item short-form survey for measuringheadache impact: the HIT-6. Quality of Life Research. 2003; 12: 8: 963—974.184.Kim S.Y. The role of headache chronicity among predictors contributing toquality of life in patients with migraine: a hospital-based study.
Headache Pain. 2014; 15;68.101185.Krymchantowski A.V., Silva M.T., Barbosa J.S., Alves L.A. Amitriptyline versusamitriptyline combined with fluoxetine in the preventative treatment of transformedmigraine: a doubleblind study/ Headache 2002; 42: 510–514.186.Krymchantowski A.V., Hampshire F. Polytherapy in migraine prevention.
Clinicalexperience with the combination of a tricyclic antidepressant plus a calcium channelblocker. Headache 2004; 44: 499–500.187.Läinez M.J., Lopez A., Pascual A.M. Effects on productivity and quality of lifeof rizatriptan for acute migraine: a workplace study. Headache. 2005. 883-890.188.Lante´ri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment,disability, and economic burden associated with chronic daily headache, focusing onchronic migraine with or without medication overuse: a systematic review. Cephalalgia2011; 31: 837-850.189.Lemstra M., Srewart B., Olszynski W.P.
Effectiveness of multidisciplinaryintervention in the treatment of migraine: a randomized clinical trial. Headache 2002;42:845-854.190. LebedevaE.R., Kobzeva N.R., Gilev D., Olesen J. Prevalence of primary headachedisorders diagnosed according to ICHD-3 beta in three different social groups. Cephalalgia2015; 36(6): 579–588.191.Lipton R.B. Chronic migraine, classification, differential diagnosis, andepidemiology.
J. Head and Face Pain. 2011; 51: 77-83.192.Lipton RB. Risk factors for and management of medication-overuse headache.Continuum (Minneap Minn). 2015; 21(4 Headache): 1118-1131.193.Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraineheadache disability and health-related quality-of-life: a population-based case-control studyfrom England. Cephalalgia. 2003;23(6):441-50.194.Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A Comparison ofthe Chronic Migraine EpidemiologyandOutcomes(CaMEO)StudyandAmerican Migraine Prevalence and Prevention (AMPP) Study: Demographics andHeadache-Related Disability. Headache.
2016; 56(8): 1280-1289.102195.Lipton RB,RosenNL,AilaniJ,DeGryseRE,GillardPJ,VaronSF.OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine overone year of treatment: Pooled results from the PREEMPT randomized clinical trialprogram. Cephalalgia. 2016; 36(9): 899-908.196.Lyngberg A.C., Rasmussen B.K., Jorgensen T., Jensen R. Has the prevalence ofmigraine and tension-type headache changed over a 12-year period? A Danish populationsurvey. European Journal of Epidemiology.
2005; 20(3): 243–249.197.Lucchesi C. Fatigue, sleep-wake pattern, depressive and anxiety symptoms andbody-mass index: analysis in a sample of episodic and chronic migraine patients. NeurolSci. 2016; №6; 987-989.198. Maassenvan den Brink A. CGRP PNS models in headache.
J Headache Pain. 2017;18(Suppl 1): 111. S7199.Martin B.C., Pathak D.S., Sharfman M.I. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache. 2000; 40: 3: 204—215.200.May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat RevNeurol. 2016;12(8):455-64.201.Meletiche D.M., Lofland J.H., Young W.B. Quality of life differences betweenpatients with epizodic and transformed migraine. Headache 2001. Vol.41. P. 573-578.202.Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF, Stokes M,Lipton RB. Direct and Indirect Costs of Chronic and Episodic Migraine in the UnitedStates: A Web-Based Survey.
Headache. 2016;56(2):306-22.203.Monzon M.J., Lainez M.J.A. Quality of life in migraine and chronic dailyheadache patients. Cephalagia. 1998. Vol.18. P. 638-643.204.Munakata J., Hazard E., Serrano D. et al. Economic burden of transformedmigraine: results from the American Migraine Prevalence and Prevention (AMPP) study.Headache. 2009; 49: 498—508.205.Natoli J.L., Manack A., Dean B. et al. Global prevalence of chronic migraine: аsystematic review.
Cephalalgia. 2010; 30: 599—609.103206. NegroA. OnabotulinumtoxinA for migraine treatment. J Headache Pain. 2017;18(Suppl 1): 111. S55.207.Obermann M., Katsarava Z. Management of medication overuse headache.Expert Review Of Neurother apeutics. 2007; 7(9): 1145–1155.208.Olesen J., Bousser M.G., Diener H.C., Dodick D., First M., Goadsby P.J., GöbelH., Lainez M.J., Lance J.W., Lipton R.B., Nappi G., Sakai F., Schoenen J.,Silberstein S.D.,Steiner T.J. Headache Classification Committee, New appendix criteria open for a broaderconcept of chronic migraine.
Cephalalgia. 2006; 26: 6: 742—746.209.Ohbu S., Igarashi H., Okayasu H. Development and testing of the Japaneseversion of the migraine-spesific quality of life instrument. Qual. Life Res. 2004. Vol.13,№8. P. 1489-93.210.Osipova V.V., Snopkova E., Tabeeva G. Migraine in the Elderly.
In: Siva A.,Lampl C. (eds) Case-Based Diagnosis and Management of Headache Disorders. Headache.Series editors: P. Marteletti, R. Jensen, Springer International Publishing. 2015: 109-118.211.Osterhaus J.T., Townsend R.J. The quality of life of migraineurs: A crosssectionalprofile. Cephalalgia.
1991. (Suppl. 11) p. 103-104.212.Pascual J., Rivas M.T., Leira R. Testing the combination betablocker plustopiramate in refractory migraine. Acta Neurol. Scand 2007; 115: 81–83.213.Passchier J., H. van der Helm-Hylkema, Orlebeke J.F. PsychophysiologicalCharacteristics of Migraine and Tension Headache Patients: Differential Effects of Sex andPain State. Neurol Neurosung Psychiat 2001; 70: 244-46.214.Patrick D.L., Hurst B.C., Hughes J. Further development and testing of themigraine-specific quality of life (MSQOL) measure. Headache.
2000. Vol.40, №7. Р. 550560.215.Payne K.A. The International Burden of Migraine Study (IBMS): study design,methodology, and baseline cohort characteristics. Cephalalgia. 2011; 1116-1130.216.Peterlin B.L., Calhoun A.H., Sherry S., Mathew N.T. Rational combinationtherapy in refractory migraine.
Headache 2008; 48: 805–819.217. PuleddaF, Goadsby PJ. An Update on Non-Pharmacological Neuromodulation for theAcute and Preventive Treatment of Migraine. Headache. 2017;57(4):685-691.104218.Raggi A, Giovannetti AM, Quintas R, D’Amico D, Cieza A, Sabariego C,Bickenbach JE, Leonardi M. A systematic review of the psychosocial difficulties relevant topatients with migraine. J Headache Pain 2012;13: 595–606.219.Rasmussen B.K., Jensen R., Schroll M., Olesen J.
Epidemiology of headache in ageneral population—a prevalence study. Journal of Clinical Epidemiology 1991; 44:11471157.220. Rendas-BaumR., Yang M., Varon S.F. et al. Validation of the Headache Impact Test(HIT-6) in patients with chronic migraine. Health and Quality of Life Outcomes 2014;12:117.221.Santanello N. C., Hartmaier S.L., Epstein R.S., Silberstein S.D. Development of abrief 24-hour migraine-specific quality of life questionnaire.
Headache.1995; 320-329.222.Seng EK, Buse DC, Klepper JE, J Mayson S, Grinberg AS, Grosberg BM, Pavlovic JM,RobbinsMS,VollbrachtSE,LiptonRB.PsychologicalFactorsAssociatedWith Chronic Migraine and Severe Migraine-Related Disability: An Observational Study ina Tertiary Headache Center. Headache.
2017; 57(4):593-604.223.Silberstein SD. Considerations for management of migraine symptoms in the primarycare setting. Postgrad Med. 2016;128(5):523-37.224.Silberstein S.D., Blumenfeld A.M., Cady R.K., Turner I.M., Lipton R.B., DienerH.C., Aurora S.K., Sirimanne M., DeGryse R.E., Turkel C.C., Dodick D.W.Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooledsubgroup analysis of patients who had acute headache medication overuse at baseline.
JNeurol Sci. 2013; 15: 331: 1—2: 48—56.225. SilbersteinS., Diener H.C., Lipton R., Goadsby P., Dodick D., Bussone G., Freitag F.,Schwalen S., Ascher S., Morein J., Greenberg S., Biondi D., Hulihan J. Epidemiology, riskfactors, and treatment of chronic migraine: a focus on topiramate. Headache 2008; 48(7):1087-1095.226.Silberstein S.D., Lipton R.B., Solomon S., Mathew N.T. Classification of dailyand near daily headaches: proposed revisions to the IHS criteria. Headache 1994; 34: 1-7.105227.Silberstein S.D., Lipton R.B., Sliwinski M.
Classification of daily and near dailyheadaches: field trial of revised IHS criteria. Neurology 1996; 47: 871-875.228.Silberstein S.D., Lipton R.B., Saper J.R. Chronic daily headache includingtransformed migraine, chronic tension-type headache and medication overuse headache. In:S.D. Silberstein, R.B. Lipton, D.W. Dodick (eds) Wolff’s headache and other head pain.Oxford University Press, New York. 2008; 315—377.229.Silberstein S., Lipton R., Dodick D., Freitag F., Mathew N., Brandes J., Bigal M.,Ascher S., Morein J., Wright P., Greenberg S., Hulihan J. Topiramate treatment of chronicmigraine: a randomized, placebo-controlled trial of quality of life and other efficacymeasures. Headache.
2009; 49: 8: 1153—1162.230.Silva H.M. Jr., Garbelini RP, Teixeira SO, Bordini CA, Speciali JG. Effect ofepisodic tension-type headache on the health-related quality of life in employees of aBrazilian public hospital. Arq Neuropsiquiatr. 2004; 62(3В): 769-773.231.Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS,Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA.Practice guideline update summary: Botulinum neurotoxin for the treatment ofblepharospasm, cervical dystonia, adult spasticity, and headache: Report of the GuidelineDevelopment Subcommittee of the American Academy of Neurology. Neurology 2016;86(19): 1818-1826.232. SinghNN, Sahota P.
Sleep-related headache and its management. Curr Treat OptionsNeurol. 2013 Dec;15(6):704-22. doi: 10.1007/s11940-013-0258-1.233.Solomon G.D., Santanello N.Impact of migraine and migraine therapy onproductivity and quality of life. Neurology. 2000. Vol. 55, №9. P. 29-35.234.Stewart W., Bruce C., Manack A. et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
